Boothbay Fund Management’s Viridian Therapeutics VRDN Stock Holding History

Boothbay Fund Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-51,300	Closed	-$983K	–	1816
2024 Q4	$983K	Sell	51,300 -7,200	-12%	-$157K	0.02%	641
2024 Q3	$1.33M	Buy	58,500 +32,000	+121%	+$523K	0.03%	664
2024 Q2	$345K	Buy	+26,500	New	+$367K	0.01%	1111
2022 Q3	–	Sell	-39,700	Closed	-$459K	–	2628
2022 Q2	$459K	Buy	+39,700	New	+$534K	0.01%	1222

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Boothbay Fund Management's VRDN Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 541,058 shares worth $9.94M. The stake represents 0.13% of the portfolio and ranks #167 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in VRDN as recently as Q3 2025.

Boothbay Fund Management first reported a position in VRDN in Q3 2024 and has held it in 6 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Boothbay Fund Management held 541,058 shares of Viridian Therapeutics worth $9.94M as of Q2 2026.
Viridian Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Viridian Therapeutics made up 0.13% of Boothbay Fund Management's portfolio in Q2 2026, its #167 holding.
Boothbay Fund Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 6 quarters since.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.